The past few decades have witnessed extraordinary biomedical breakthroughs in treatments for cardiovascular disease, cancer, and infectious diseases like HIV and hepatitis C. But progress against Alzheimer’s disease and related disorders remains frustratingly elusive. This is worrisome because without an effective intervention, dementia prevalence will triple over the next several decades, raising the specter of an aging America with healthy bodies housing deteriorating minds.
Still, there are reasons for optimism, particularly in diagnostics and early treatments – even before cognitive symptoms are present. But when these advances become available, will policymakers be ready with answers on how to value them and have policies in place to support access and prevention? Will novel payment approaches be supported? Will the healthcare system be ready to meet demand?
Join the USC-Brookings Schaeffer Initiative for Health Policy on Sept. 1, 2020, for a conversation on the hopeful signs in clinical development and the policy challenges of how to make Alzheimer’s disease treatments and diagnostics readily available.
- Event Date
- Tuesday, September 01, 2020
9:00 AM - 10:45 AM Pacific
9:00 a.m. PT - Welcome
- Leonard D. Schaeffer, Trustee, Brookings Institution, and Trustee and Judge Robert Maclay Widney Chair, University of Southern California
9:05 a.m. - Clinical Outlook: Potential Breakthroughs in Alzheimer’s Disease
- Paul Aisen, MD, Founding Director, USC Alzheimer’s Therapeutic Research Institute (ATRI), and Professor of Neurology, Keck School of Medicine of USC
9:20 a.m. - Panel: Clinical Promise of New Treatments for Alzheimer’s Disease
- Moderator: Dana Goldman, PhD, Director, USC Schaeffer Center, Nonresident Senior Fellow in Economic Studies, The Brookings Institution, and Interim Dean, USC Price School of Public Policy, University of Southern California
- Paul Aisen, MD
- Sharon Cohen, MD, Medical Director, Toronto Memory Program, and Assistant Professor, Division of Neurology, University of Toronto
- Heather Snyder, PhD, Vice President of Medical & Scientific Relations, Alzheimer’s Association
9:55 a.m. - How to Value Treatments for Alzheimer’s Disease
- Darius Lakdawalla, PhD, Director of Research, USC Schaeffer Center, and Professor, USC School of Pharmacy and USC Price School of Public Policy
10:10 a.m. - Panel: Public Policies to Support Access
- Moderator: Dana Goldman, PhD
- Darius Lakdawalla, PhD
- Steve Miller, MD, Chief Clinical Officer, Cigna Corporation
- Sarah Lenz Lock, JD, Senior Vice President for Policy and Brain Health in the Policy, Research and International Affairs Division, AARP